These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 36148775)

  • 1. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.
    Badmus OO; Hillhouse SA; Anderson CD; Hinds TD; Stec DE
    Clin Sci (Lond); 2022 Sep; 136(18):1347-1366. PubMed ID: 36148775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic-associated fatty liver disease and lipoprotein metabolism.
    Heeren J; Scheja L
    Mol Metab; 2021 Aug; 50():101238. PubMed ID: 33892169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid Disorders and Metabolic-Associated Fatty Liver Disease.
    Anwar SD; Foster C; Ashraf A
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):445-457. PubMed ID: 37495336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis.
    Lutsiv T; McGinley JN; Neil ES; Foster MT; Thompson HJ
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
    Geisler CE; Renquist BJ
    J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triglyceride Metabolism in the Liver.
    Alves-Bezerra M; Cohen DE
    Compr Physiol; 2017 Dec; 8(1):1-8. PubMed ID: 29357123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Insulin Resistance in MAFLD.
    Sakurai Y; Kubota N; Yamauchi T; Kadowaki T
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
    Ipsen DH; Lykkesfeldt J; Tveden-Nyborg P
    Cell Mol Life Sci; 2018 Sep; 75(18):3313-3327. PubMed ID: 29936596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palmitoleic Acid Decreases Non-alcoholic Hepatic Steatosis and Increases Lipogenesis and Fatty Acid Oxidation in Adipose Tissue From Obese Mice.
    Cruz MM; Simão JJ; de Sá RDCC; Farias TSM; da Silva VS; Abdala F; Antraco VJ; Armelin-Correa L; Alonso-Vale MIC
    Front Endocrinol (Lausanne); 2020; 11():537061. PubMed ID: 33117273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.
    Koo SH
    Clin Mol Hepatol; 2013 Sep; 19(3):210-5. PubMed ID: 24133660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of hepatic steatosis by dietary fatty acids.
    Ferramosca A; Zara V
    World J Gastroenterol; 2014 Feb; 20(7):1746-55. PubMed ID: 24587652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.
    Kawano Y; Cohen DE
    J Gastroenterol; 2013 Apr; 48(4):434-41. PubMed ID: 23397118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hepatocyte IKK:NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis.
    Heida A; Gruben N; Catrysse L; Koehorst M; Koster M; Kloosterhuis NJ; Gerding A; Havinga R; Bloks VW; Bongiovanni L; Wolters JC; van Dijk T; van Loo G; de Bruin A; Kuipers F; Koonen DPY; van de Sluis B
    Mol Metab; 2021 Dec; 54():101349. PubMed ID: 34626855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Investigation of High-Fat Diet-Induced Hepatic Lipid Dysfunctions.
    Korach-André M
    Methods Mol Biol; 2020; 2164():109-119. PubMed ID: 32607888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
    Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate immune regulatory networks in hepatic lipid metabolism.
    Bai L; Li H
    J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism.
    Nagarajan SR; Cross E; Sanna F; Hodson L
    Proc Nutr Soc; 2022 Mar; 81(1):1-11. PubMed ID: 34726148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in research of the mechanisms related with the hepatic steatosis in the nonalcoholic fatty liver disease].
    Shi LJ; Song GY
    Sheng Li Ke Xue Jin Zhan; 2013 Dec; 44(6):415-9. PubMed ID: 24665739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.